|
|
|
|
|
HIGHLIGHTS FROM THE 2024 AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEETING |
|
|
|
|
| A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients with Microhematuria: The STRATA: Safe Testing of Risk for Asymptomatic Microhematuria trial |
| Yair Lotan, MD |
| Yair Lotan presented findings from the STRATA trial at AUA 2024, comparing Cxbladder Triage (CxbT) to cystoscopy in patients with microhematuria. The trial demonstrated a 59% relative reduction in cystoscopy rates among low-risk patients using CxbT, which had a sensitivity of 90% and a remarkable negative predictive value (NPV) of 99%. |
|
|
|
|
|
| Pivotal Results from BOND-003: A Phase 3, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
|
| Mark Tyson II, MD, MPH
|
| Mark Tyson presented pivotal results from BOND-003, a phase 3 study evaluating intravesical cretostimogene grenadenorepvec for high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) at the 2024 AUA annual meeting. Cretostimogene demonstrated a 75.2% complete response rate at any time based on central review, with durable responses observed over time.
|
|
|
|
|
|
| Effects of Neoadjuvant Chemotherapy on Rates of Depression in Muscle Invasive Bladder Cancer |
| Matthew DeSanto, MD, Ph.D. |
| Matthew DeSanto presented findings at the 2024 AUA meeting indicating that neoadjuvant chemotherapy followed by radical cystectomy in MIBC patients is associated with an increased risk of depression within 3 months post-surgery. Their retrospective cohort study identified a higher incidence of depressive episodes and suicide attempts in patients who received NAC compared to those who did not. |
|
|
|
|
|
| Smoking Status is Associated with Poor Mental Health in Bladder Cancer Patients and Survivors
|
| Khalid Alkhatib, MD, MMSc |
| Khalid Alkhatib presented findings at the 2024 AUA meeting showing that current smoking status is associated with poorer mental health among bladder cancer patients. Using data from the CDC National Behavioral Risk Factor Surveillance System, they identified a link between being a current smoker and experiencing adverse mental health. This study underscores the importance of integrating mental health screening and smoking cessation programs into the follow-up care of bladder cancer patients to improve overall well-being and oncologic outcomes.
|
|
|
|
|
|
| The International Bladder Cancer Group Intermediate-Risk Non-Muscle Invasive Bladder Cancer Scoring System Predicts the Need for Intervention for Patients on Active Surveillance
|
| Wei Shen Tan, MBBCh
|
| Wei Shen Tan presented findings showing that the International Bladder Cancer Group (IBCG) Intermediate-risk NMIBC scoring system can predict the need for delayed TURBT among patients with low-grade Ta/T1 disease managed with active surveillance. Patients with fewer risk factors from the IBCG scoring system were more likely to continue active surveillance without intervention, while those with more risk factors were more likely to require delayed TURBT.
|
|
|
|
|
|
|
|
|
|
|
| Challenging the Paradigm of "BCG Unresponsive" Bladder Cancer: Does Additional BCG Have an Effect?
|
| Amanda Myers, MD
|
| Amanda Myers presented findings at the 2024 AUA meeting showing that rescue BCG therapy can have durable efficacy in appropriately selected patients with "BCG unresponsive" non-muscle invasive bladder cancer. The study included 35 patients who received rescue BCG as primary therapy, with 75% achieving disease-free status and a median disease-free survival of 75 months. These results challenge current paradigms that recommend against further BCG therapy and highlight the potential benefit of this approach in select patients.
|
|
|
|
|
|
| N-803 plus BCG Complete Response Rate in Non Muscle Invasive Bladder Cancer CIS Subjects: BCG Refractory, Relapsed, Checkpoint Failure, and Chemotherapy Failure; Updated Results (QUILT 3.032) |
| Patrick Soon-Shiong, MD |
| Patrick Soon-Shiong presented updated results from the QUILT 3.032 trial at AUA 2024, evaluating N-803 plus BCG in patients with BCG-unresponsive high-grade NMIBC. The study demonstrated a complete response rate of 65% in patients with BCG-unresponsive CIS, with higher rates seen in subgroups with more prior BCG doses. |
|
|
|
|
|
| Replacing ReTUR with Cystoscopy in High-Grade T1 NMIBC Patients: Confirmatory Results from the HuNIRe Trial |
| Alessio Finocchiaro, MD |
| Alessio Finocchiaro presented confirmatory results from the HuNIRe trial at AUA 2024, which focused on replacing re-staging TURBT with cystoscopy in high-grade T1 NMIBC patients. The trial demonstrated that selectively offering re-staging TURBT only to patients with positive cystoscopy or urine cytology, instead of routine re-staging for all, did not lead to worse cancer outcomes in terms of recurrence-free survival at a median follow-up of 17.5 months. |
|
|
|
|
|
